<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779831</url>
  </required_header>
  <id_info>
    <org_study_id>AA16795</org_study_id>
    <nct_id>NCT00779831</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions</brief_title>
  <official_title>Comparative, Randomized, Single Dose, 2 Way Crossover Bioavailability Study of Ranbaxy and Warner - Lambert (Sudafed ® 12 Hour) 120 mg Pseudoephedrine Hydrochloride Extended - Release Tablets in Healthy Adult Volunteers Under Fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare bioavailability of Pseudoephedrine hydrochloride extended release tablets (Ranbaxy&#xD;
      Laboratories Limited) against reference product Sudafed ® 12-hour tablets 120 mg&#xD;
      (Warner-Lambert) under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open label, randomized, single dose, 2-way crossover, relative bioavailability&#xD;
      study performed on a total of 36 healthy adult subjects (20 males and 16 females). Thirty&#xD;
      five (35) subjects (19 males and 16 females) completed the clinical phase of the study. In&#xD;
      each period, subjects were housed from at least 10 hours before dosing until after the 36&#xD;
      hour blood draw. Single oral 120 mg Pseudoephedrine hydrochloride doses were separated by a&#xD;
      washout period of 7 days.&#xD;
&#xD;
      A total of thirty six (36) subjects (20 males and 16 females) were enrolled in the study. Out&#xD;
      of which a total of thirty five (35) subjects (19 males and 16 females) completed the&#xD;
      clinical phase of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120 mg Pseudoephedrine hydrochloride extended release tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects enrolled in this study met all inclusion and exclusion criteria, and were&#xD;
             judged by the investigator to be normal, healthy volunteers&#xD;
&#xD;
        Subjects were included in the study if they met all of the following criteria:&#xD;
&#xD;
          1. Healthy adult male or female volunteers , 18 to 55 years of age&#xD;
&#xD;
          2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal&#xD;
             weights (table of 'Desirable Weights of Adults', Metropolitan Life Insurance Company,&#xD;
             1983)&#xD;
&#xD;
          3. Medically healthy subjects with clinically normal laboratory profiles and ECGs&#xD;
&#xD;
          4. Females of child bearing potential should either be sexually inactive (abstinent) for&#xD;
             14 days prior to the first dose and throughout the study or be using one of the&#xD;
             following acceptable birth control methods:&#xD;
&#xD;
               1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral&#xD;
                  oophorectomy) 6 months minimum&#xD;
&#xD;
               2. IUD in place for at least 3 months&#xD;
&#xD;
               3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to&#xD;
                  the first dose and throughout the study&#xD;
&#xD;
               4. Surgical sterilization of the partner (vasectomy for 6 months minimum)&#xD;
&#xD;
               5. Hormonal contraceptives for at least 3 months prior to the first dose of the&#xD;
                  study&#xD;
&#xD;
               6. Other birth control methods may be deemed acceptable&#xD;
&#xD;
          5. Post menopausal women with amenorrhea for at least 2 years will be eligible&#xD;
&#xD;
          6. Voluntarily consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects were excluded from the study if there was evidence of any of the following at&#xD;
             screening or at any time during the study:&#xD;
&#xD;
               1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
                  hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,&#xD;
                  or psychiatric disease&#xD;
&#xD;
               2. In addition, history or presence of:&#xD;
&#xD;
                    1. Alcoholism or drug abuse within the past year&#xD;
&#xD;
                    2. Hypersensitivity or idiosyncratic reaction to Pseudoephedrine or any other&#xD;
                       sympathomimetic amines&#xD;
&#xD;
                    3. Glaucoma or hypermetropia&#xD;
&#xD;
               3. Female subjects who are pregnant or lactating&#xD;
&#xD;
               4. Positive results on HIV, HbsAg and HCV tests&#xD;
&#xD;
               5. Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of&#xD;
                  stopping use of an MAO inhibitor, or any sympathomimetic amines&#xD;
&#xD;
               6. Subjects who have been on a special diet (for whatever reason) during the 28 days&#xD;
                  prior to the first dose and throughout the study&#xD;
&#xD;
               7. Subjects who through completion of the study, would have donated in excess of:&#xD;
&#xD;
          -  500 mL of blood in 14 days&#xD;
&#xD;
          -  1500 mL of blood in 180 days&#xD;
&#xD;
          -  2500 mL of blood in 1 year. 8. Subjects who have participated in another clinical&#xD;
             trial within 28 days prior to the first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Saint-Laurent</city>
        <state>Quebec</state>
        <zip>H4R2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 23, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research labs</organization>
  </responsible_party>
  <keyword>Bioequivalence Pseudoephedrine hydrochloride 120 mg extended release tablets</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

